Role of complement in humoral immunity

Curr Opin Organ Transplant. 2023 Aug 15. doi: 10.1097/MOT.0000000000001095. Online ahead of print.ABSTRACTPURPOSE OF REVIEW: Antibody-mediated rejection (AMR) after solid organ transplantation remains an unsolved problem and leads to poor early and late patient outcomes. The complement system is a well recognized pathogenic mediator of AMR. Herein, we review the known molecular mechanisms of disease and results from ongoing clinical testing of complement inhibitors after solid organ transplant.RECENT FINDINGS: Activation and regulation of the complement cascade is critical not only for the terminal effector function of donor-specific antibodies, but also for the regulation of T and B cell subsets to generate the antidonor humoral response. Donor-specific antibodies (DSA) have heterogenous features, as are their interactions with the complement system. Clinical testing of complement inhibitors in transplant patients have shown good safety profiles but mixed efficacy to date.SUMMARY: The complement cascade is a critical mediator of AMR and clinical trials have shown early promising results. With the steady emergence of novel complement inhibitors and our greater understanding of the molecular mechanisms linking complement and AMR, there is greater optimism now for new prognostic and therapeutic tools to deploy in transplant patients with AMR.PMID:37582054 | DOI:10.1097/MOT.0000000000001095
Source: Current Opinion in Organ Transplantation - Category: Transplant Surgery Authors: Source Type: research